Chronic, recurrent Lymphocytic Leukemia Active Not Recruiting Phase 2 Trials for Obinutuzumab (DB08935)

Also known as: Recurrent Chronic Lymphocytic Leukemia

IndicationStatusPhase
DBCOND0112002 (Chronic, recurrent Lymphocytic Leukemia)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02225275Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTreatment